It is worth noting that within the limitations of sample size, we observed a trend towards an increase in the mutational burden at recurrence that did not reach statistical significance despite the use of TMZ as adjuvant therapy in 10/16 (63%) pHGGs.
← all excerpts
Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
1
—
—